MetaCap

Allarity Therapeutics (ALLR) vs Bolt Biotherapeutics (BOLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.6 million), about 1.0 times the size. Bolt Biotherapeutics converts more of its revenue into profit, with a net margin of -433.7% versus -3509.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLR-20.22%BOLT+36.39%
+88%+31%-25%
Oct 7, 20261 yearNov 20, 2026
ALLR-20.71%BOLT+19.46%
+64%+20%-25%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLR versus BOLT key metrics
MetricALLRBOLT
Share price$0.785$4.91
Market cap$12.56M$12.80M
1-day change-9.25%-2.96%
YTD return-27.31%—
1-year return-25.94%—
EPS (TTM)$-0.79$-14.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.00K$7.70M
Revenue growth (YoY)—+0.07%
Net income (latest FY)$-11.23M$-33.38M
Operating margin-3939.06%-469.30%
Net margin-3509.69%-433.74%
52-week high$1.84$7.78
52-week low$0.769$3.10
Distance from 52-week high-57.34%-36.89%
Analyst consensusnonenone
Avg. price target upside+1301.27%+490.63%
Average volume131.74K257.43K
Shares outstanding16.00M2.61M
Employees723
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bolt Biotherapeutics is more profitable, keeping -433.7 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.

About Allarity Therapeutics

ALLR stock →

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

ALLR vs BOLT FAQ

Which is bigger, Allarity Therapeutics or Bolt Biotherapeutics?

Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.56M for Allarity Therapeutics (ALLR).

Are Allarity Therapeutics and Bolt Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons